Funding
Series D+Series E · Biotech

LifeMine Therapeutics announces $263m across Series D and E

Milky Way Investments, Bezos Expeditions and other investors participated in the combined funding.

Updated Oct 16, 2026By RoundOS Funding desk

LifeMine Therapeutics announced $263 million across Series D and Series E financing on August 5. Participants included Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus and ARCH Venture Partners. The company develops therapeutics derived from fungal genomes for transplant rejection.

Funding history

Series D+Series E · This round$263M

Sources

  1. LifeMine Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related